Introduction: multidrug resistance among Escherichia coli causing Urinary Tract Infections (UTIs) is a major public health problem, threatening the
Introduction
Escherichia coli strains are common bacteria that inhabit human gastrointestinal tract, whilst they are often harmless commensals; they can cause multitude of infections such as urinary tract infections (UTIs), meningitis, diarrhoea and septicemia [1] . Their harmless strains can remain commensals as long as they do not acquire genetic elements encoding virulence factors which may eventually result in these diseases [2] . The alarming increase in the rate at which these strains acquire antibiotic resistance genes has limited therapeutic options especially for UTIs for which extensive use of antibiotics has been witnessed in both community and hospital settings [1, 3] .
Extended Spectrum Beta Lactamases (ESBLs) expression among E. coli strains encodes resistance to oxyiminocephalosporins and many other important groups of antibiotics, thereby causing impediment to treatment of its infections [4, 5] . Also, the carbapenems which are the last resort in the effective treatment of severe ESBL-producing E. coli infections, have recently witnessed rise in resistance by E. coli strains that produced carbapenem-hydrolyzing enzymes [4, 6, 7] . Aminoglycosides have been an essential component of the antibiotic armory in the treatment of serious life threatening infections and UTIs caused by E. coli, but the increasing wind of antibiotic resistance across the globe has reduced their effectiveness, rendering some members of this class of antimicrobials virtually useless in certain E. coli infections [8] . The ineffectiveness of aminoglycosides has been attributed to the expression of aminoglycoside-modifying enzymes {nucleotidyltranferases (ANTs), phosphotransferases (APHs), or acetyltransferases (AACs)} which catalyze the modification of the 2-deoxystreptamine nucleus or the sugar moieties [9] . An increase in resistance to gentamicin has been reported amongst isolates of E. coli associated with UTIs in many parts of Nigeria and other African countries [10] [11] [12] .
The advent of fluoroquinolones, the new generation of quinolones antimicrobial agents brought a ray of hope to the treatment of various infections caused by multi-drug resistant bacteria and became the drug of choice for the empiric therapy of most serious life threatening infections [1, 3] . However, the extensive use of these agents in clinical settings has made bacteria to develop resistance to them all over the world [3, 13] . Fluoroquinolones are one of the most widely used drugs in the treatment of UTIs but their frequent use in both community and hospital settings has led to a dramatic rise in resistance amongst E. coli causing UTIs [7, 12, 13] . Quinolones inhibit the DNA replication in E. coli strains by targeting the bacterial DNA gyrase (topoisomerase II) and topoisomerase IV (parC) enzymes but mutations in the specific domains of gyrA, gyrB, parC and parE can cause changes in single amino acid of either gyrase or topoisomerase IV leading to the bacterial resistance to quinolones [14] . High-level of fluoroquinolone resistance in E. coli strains has been attributed to multiple mutations in the quinolone-determining resistant regions (QRDR) of topoisomerase enzymes [1, 9] . Various community and hospital based studies from Nigeria and other African countries have reported a varying prevalence of phenotypic and genotypic ESBL producing enterobacteriaceae [15] [16] [17] [18] [19] . However, information on molecular characterization of E. coli isolates causing UTIs from Nigeria is sparse. Therefore, this study was carried out to investigate the molecular characteristics of drug resistance in E. coli isolated from patients with UTIs in Port Harcourt, Nigeria.
Methods
Bacterial strains: a total of one hundred and forty urine samples obtained from patients of average age 29. 6 The amplified PCR products were analyzed on a 1.5% w/v agarose gel stained with ethidium bromide (10 µg/ml) and electrophoresis was performed in 0.5X TBE buffer at 100 V for 60 minutes with a 100 bp DNA ladder as a molecular marker, and the gels were subsequently visualized in a gel documentation system (Alpha Innotech, AlphaImager 3400).
Amplification of the quinolone resistance determining regions (QRDRs): the QRDRs of gyrA and parC genes were amplified in a representative batch of isolates as previously described by Roderova et al. [1] and Chu et al. [25] for gyrA gene and Vila et al. [26] for parC genes using the primers in Table 1 . For each 25 μl reaction mixture containing a strain's DNA template, the condition used for the amplification of gyrA was initial denaturation at 94°C for 3 min, 30 cycles of 92°C for 1 min; 64°C for 1 min; 74°C for 2 min and a final cycle of 74°C for 10 min. The condition for parC was 30 cycles at 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min.
Amplification of the plasmid mediated quinolone resistance (PMQRs): the PMQRs genes for qnrB, qnrD, qnrS and aac(6')-Ib were amplified as previously described by Robicsek et al. [27] and Guessennd et al. [28] using the primers in Amplification of the aminoglycosides resistance genes: the strains were screened for the presence of aminoglycosides resistance genes by amplifying the genes for aphA2, aadA1, aadA2, aacC2 and aac(3)-IV using the primers described in Table 1 
Results
In total, only 25 non-duplicate E. coli isolates from patients with UTIs were identified. The antimicrobial resistance profile of the isolates revealed a high resistance (60 -76%) to co-trimoxazole (folate inhibitor) and quinolones-fluoroquinolones group, moderate resistance to gentamicin and low resistance to taxobactam/piperacillin and the cephalosporins. All isolates were susceptible to cefoperazone/sulbactam, amikacin, nitrofurantoin, colistin and carbapenems as described in Figure 1 . On PCR screening of gyrA and parC genes in eight randomly selected isolates, all were found to be positive. Three (37.5%) of these isolates also carried at least two of the screened β-lactamase and aminoglycosides encoding genes ( Table 3 ). The screening for PMQRs genes revealed the presence of qnr variants (qnrB, qnrD and qnrS) and aac(6')-Ib genes in 7 (28%) and 3 (12%) of the isolates respectively. These were qnrB (n=1), qnrD (n=5) qnrS (n=4). Three isolates carried both qnrD and qnrS while another carried only qnrS.
Two other isolates carrying qnrD also had aac(6')-Ib gene while the isolate carrying qnrB also had aac(6')-Ib. All these isolates had ciprofloxacin MICs of 256 -512 µg/ml, and also carried at least two of the screened ESBLs encoding genes ( Table 3 ). The prevalence of
PMQRs genes among the MDR isolates was 7 (53.8%) and the MDR isolates were observed to significantly possess at least one of the ESBL genes and one of the PMQRs genes (p = 0.015). All the gentamicin resistant isolates possessed aacC2 gene with one or more of the other screened aminoglycosides genes except aphA2 gene ( Figure 3 ). The isolates that possessed aacC2gene were significantly associated with MDR (p = 0.017) than those that possessed other screened aminoglycosides genes. Four (36.4%) of the isolates with MICs 128 -512 µg/ml had aadA1, aadA2 and aacC2 genes with at least two of the screened β-lactamase encoding genes ( Table 3 ). The MDR isolates were observed to significantly possess at least one of the ESBL genes and one of the aminoglycosides genes (p = 0.017).
Discussion
Escherichia coli is one of the major causes of UTI affecting humans of This increasing level of resistance has also been reported in recent studies from other developing countries where there is no strict policy on the use of antibiotics in their communities [7, 12, 30] .
The potentially high effectiveness of taxobactam/piperacillin, cefoperazone/sulbactam, amikacin, nitrofurantoin, colistin and all the tested carbapenems on the urinary E. coli strains in this study support previous findings [7, 12, 18, 30] . Hence, any of these agents or their combinations can be used in the empiric treatment of urinary tract infections. The effectiveness of nitrofurantoin, although one of the oldest UTIs drugs, is not unlikely to be attributed to its unpleasant side effects which has largely discouraged its frequent misuse and this supports previous findings [7, 11, 18] . The prevalence of multiple drug resistance among the studied isolates was 52% which is lower than the previously reported findings of 85-100% in various parts of Nigeria and other African countries [10-12, 15, 30] . The observed differences might be due to the differences in the screening techniques at various centres of study. However, the observed prevalence of MDR indicates that the isolates might have been inadvertently exposed to these antimicrobials either from the clinics or agricultural products since E. coli can easily get exposed to the drugs used in animal husbandry and food industry through ingestion. Hence, control use of antimicrobials in both agricultural and clinical settings could reduce the prevalence of MDR among uropathogens.
The phenotypic detection of ESBLs in this study was identified in 24%
of the isolates using only cefotaxime and its clavulanic acid combination discs. However, it has been reported that the use of multiple agents including aztreonam, ceftazidime and cefotaxime in the screening for ESBLs enhances highest rates of detection among the isolates [7, 20] . This finding is higher than the previous studies in Amassoma, South-Southern Nigeria (9.6%) and in Libya In this study, the horizontally acquired quinolone resistance genes PMQRs (qnrB, qnrD and qnrS) and aac(6')-Ib) were detected among isolates that had very high ciprofloxacin MICs of 256 -512 µg/ml and all the isolates also possessed at least two of the screened ESBLs genes. This finding is similar to the previous reports of Ogbolu et al. [32] in Nigeria and Namboodiri et al. [47] in Ghana. This Increasing aminoglycoside resistance among E. coli associated diseases has been widely reported globally. This study revealed the presence of aacC2, aadA1 and aadA2 as the prominent genes among the isolates with high level of MICs 128-512µg/ml. These isolates were equally observed to possess two or more of the screened β-lactamase genes and 8 (88.9%) of them significantly possessed multidrug resistance capability (p = 0.017). This therefore suggests that rapid dissemination of multidrug resistance genes which is favoured by the co-existence of resistance genes on same mobile genetic elements tend to limit therapeutic options against bacterial infections [48] .
Thus, there is need for strategies to control the rapid dissemination of these antibiotic resistance genes through implementation of strict guidelines for antimicrobial use in clinical practice, prevention of over the counter misuse of antibiotics and rational use of antibiotics in both human and agricultural activities.
Conclusion
This study highlights the high prevalence of ESBLs, AmpC, fluoroquinolones and aminoglycosides resistance genes co-habiting MDR uropathogenic E. coli strains suggesting an increasing UTIs treatment failure with commonly used antibiotics. Thus, the need for molecular surveillance of MDR bacteria is crucial to the optimization of empiric treatment of UTIs. It is also extremely needful to strengthen strict compliance to antibiotic stewardship and enforcement of infection control practices in all our health institutions as a means of controlling the increasing spread of MDR bacteria.
What is known about this topic
• ESBLs genes are commonly detected among antibiotic resistant E. coli strains associated with urinary tract infections, a disease that affects human of all ages;
• Treatment of UTIs in both hospital and community settings is increasingly threatened because of the increasing reports of MDR among uropathogens to the commonly available antibiotics;
• The genes encoding ESBLs in E. coli are located on transferable plasmids which also carry other aminoglycosides and fluoroquinolones genes resulting in rapid dissemination of MDR among bacterial species.
What this study adds
• There is a strong association between phenotypic expression of ESBL and the detection of blaSHV and/or blaCTX-M-15 gene in the bacteria in the study environment;
• The presence of ESBLs encoding genes in a bacterium is a possible risk factor for multidrug resistance since they are located on same plasmids that carry other resistance determinant genes;
• The detection of blaCMY-2 gene, a prominent plasmid mediated AmpC gene among UTIs associated E. coli strains carrying other ESBLs genes is the first report in Nigeria.
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